EBA, Safety and Tolerability of Sanfetrinem Cilexetil

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 21, 2022

Primary Completion Date

August 19, 2024

Study Completion Date

August 19, 2024

Conditions
Tuberculosis, Pulmonary
Interventions
DRUG

Sanfetrinem Cilexetil

"Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.~Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules"

DRUG

Rifampicin

Rifampicin will be administered at a dose of 35 mg/kg once daily for 14 days with or without sanfetrinem cilexetil.

Trial Locations (1)

7530

TASK Clinical Research Centre, Cape Town

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

TASK Applied Science

OTHER